Fasenra Pediatric Japan Post-Marketing Study(PMS)

Launched by ASTRAZENECA · May 20, 2024

Keywords

ClinConnect Summary

The Fasenra Pediatric Japan Post-Marketing Study is looking at the use of Fasenra, a medication given as an injection, in children with bronchial asthma. The main goals of this study are to find out if any unexpected side effects occur when Fasenra is used in the real world and to see how effective it is in helping children breathe better and manage their asthma. The study will include children aged 6 to under 15 years who are trying Fasenra for the first time because their asthma has not been well controlled with other treatments.

If your child is eligible and participates in this trial, you can expect to provide feedback about how they respond to the treatment, including any side effects they may experience. This is an important opportunity to help researchers understand how Fasenra works in a real-life setting, which can ultimately improve asthma care for children. There are no specific exclusions for this study, so if your child meets the age criteria and has been struggling with asthma, they may be a good fit for this trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The evaluable patients in children aged ≥6 years to \<15 years are those treated with Fasenra for the first time due to "Bronchial asthma (only the patients with intractable bronchial asthma which could not be controlled with the existing therapy)
• Exclusion Criteria:
• • none